Browsing Tag:Alzheimers

third-member-of-prestigious-fda-panel-resigns-over-approval-of-biogens-alzheimers-drug
A third member of a key advisory body to the Food and Drug Administration has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug Aduhelm, CNBC has learned.Dr. Aaron Kesselheim, professor of medicine at Harvard Medical School, said the agency's decision on Biogen was "probably the worst drug approval decision in recent US history," according...
Continue reading
0 Comments
Share
biogen-alzheimers-drug-and-the-new-battle-over-dementia-treatment
Aduhelm from BiogenSource: BiogenThe FDA approval of Biogen's Alzheimer's drug Aduhelm marked a milestone in Dr. Paul Aisen. The director of the Alzheimer's Therapeutic Research Institute at USC has focused on the treatment of neurodegenerative disease for the past three decades and in recent years has helped guide this particular drug through the various phases of clinical...
Continue reading
0 Comments
Share
biogens-alzheimers-drug-could-cost-medicare-billions-of-dollars-a-year-report
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts on Monday, June 7, 2021.Adam Glanzman | Bloomberg | Getty ImagesBiogen's expensive new Alzheimer's drug Aduhelm could cost Medicare billions of dollars, according to an analysis published Thursday by the nonprofit Kaiser Family Foundation.The Food and Drug Administration on Monday approved the company's drug, the first US...
Continue reading
0 Comments
Share
f-d-a-approves-alzheimers-drug-despite-fierce-debate-over-whether-it-works
Die Food and Drug Administration hat am Montag das erste neue Medikament gegen die Alzheimer-Krankheit seit fast zwei Jahrzehnten genehmigt, eine umstrittene Entscheidung, die trotz des Widerstands des unabhängigen Beratungsausschusses der Agentur und einiger Alzheimer-Experten getroffen wurde, die sagten, es gebe nicht genügend Beweise dafür, dass das Medikament Patienten helfen kann .Das Medikament Aducanumab, das unter dem Markennamen Aduhelm...
Continue reading
0 Comments
Share
biogens-alzheimers-drug-approved-by-fda-first-new-therapy-in-nearly-two-decades
The Food and Drug Administration approved Biogen's Alzheimer's drug aducanumab on Monday, making it the first U.S. regulator-approved drug to slow cognitive decline in people with Alzheimer's and the first new drug for the disease in nearly two decades.The FDA's decision was eagerly awaited. The drug, which is marketed under the name Aduhelm, is also expected to generate...
Continue reading
0 Comments
Share
12